Two oral presentations given by bluebird’s academic collaborators will
highlight previously presented data from bluebird bio’s ongoing gene
therapy clinical trials.
Eight additional presentations will be featured at the meeting, highlighting progress across the company’s preclinical, research and process development activities.
“As bluebird continues to build a differentiated T cell oncology
franchise, we are excited to present three oncology abstracts that
highlight our work on the next generation of technology for T cell-based
immunotherapy – including methods of generating T cells with sustained
anti-tumor activity, small-molecule regulated chimeric antigen receptors
(CARs) and genome editing to generate improved CAR T cells,” said
The abstracts are now available online on the ASGCT Annual Meeting website.
Details of bluebird bio’s oral presentations are as follows:
Title: A Phase 2/3 Study of the Efficacy and Safety of Ex Vivo
Gene Therapy With Lenti-D Lentiviral Vector for the Treatment of
Cerebral Adrenoleukodystrophy
Abstract Number: 250
Session:
Clinical Trials Spotlight Symposium
Date:
Time: 9:00 –
Location: Thurgood
Marshall North/East
Note: Data previously presented at the 2016
Title: Small Molecule-regulated Antigen Recognition System for
Inducible T Cell Targeting of Cancer Cells
Abstract Number: 277
Session:
Cancer-Immunotherapy, Cancer Vaccines I
Date:
Time: 5:15 –
Location:
Title: Clinical Outcomes of Gene Therapy with BB305 Lentiviral
Vector for Sickle Cell Disease and β-Thalassemia
Abstract
Number: 279
Session: Hematologic & Immunologic Diseases I
Date:
Time: 4:00 –
Location:
Note: Data previously presented at the 2015
Title: Towards the Clinical Application of BCMA CAR T cells: The
Importance of Reduced Tonic Signaling and Methods to Enhance Memory T
Cells
Abstract Number: 747
Session: Cancer-Immunotherapy,
Cancer Vaccines III
Date:
Time:
10:45 –
Location: Thurgood Marshall North
Details
of bluebird bio’s poster presentations are as follows:
Title: PGE2 Increases Lentiviral Vector Transduction Efficiency
of Human HSC
Abstract Number: 229
Session: Hematologic
& Immunologic Diseases I
Date:
Time:
Location: Exhibit Hall C & B South
Title: Staurosporine Increases Lentiviral Transduction of Human
CD34+ Cells
Abstract Number: 221
Session: Hematologic
& Immunologic Diseases I
Date:
Time:
Location: Exhibit Hall C & B South
Title: Qualification of a p24 ELISA Assay for Quantitation of
Total Lentiviral Vector Concentration
Abstract Number: 473
Session:
Pharmacology/Toxicology Studies or
Date:
Time:
Location: Exhibit
Hall C & B South
Title: Efficient Generation of CART Cells by Homology Directed
Transgene Integration into the TCR-Alpha Locus
Abstract Number: 323
Session:
Targeted Genome Editing II
Date:
Time:
Location: Exhibit Hall C & B South
Title: Development of a Stable Producer Cell Line for Scalable
Lentiviral Vector Production for Gene Therapy of Hemoglobinopathies
Abstract
Number: 458
Session: Vector and Cell
Engineering/Manufacturing I
Date:
Time:
Location: Exhibit Hall C & B South
Title: Characterization of Nanoparticles in Lentiviral Vector
Preparations
Abstract Number: 709
Session: Vector
and Cell Engineering/Manufacturing II
Date:
Time:
Location: Exhibit
Hall C & B South
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio’s gene therapy clinical programs include its Lenti-D™ product
candidate, currently in a Phase 2/3 study, called the Starbeam Study,
for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin® BB305
product candidate, currently in three clinical studies for the treatment
of transfusion-dependent ß-thalassemia and severe sickle cell disease.
bluebird bio’s oncology pipeline is built upon the company’s leadership
in lentiviral gene delivery and T cell engineering, with a focus on
developing novel T cell-based immunotherapies, including chimeric
antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird
bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program
partnered with Celgene. bb2121 is currently being studied in a Phase 1
trial for the treatment of relapsed/refractory multiple myeloma.
bluebird bio also has discovery research programs utilizing
megaTALs/homing endonuclease gene editing technologies with the
potential for use across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts; Seattle,
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s existing product candidates and
research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing clinical
trials, the risk that previously conducted studies involving similar
product candidates will not be repeated or observed in ongoing or future
studies involving current product candidates, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in our clinical studies, the risk that our
collaboration with
View source version on businesswire.com: http://www.businesswire.com/news/home/20160418006463/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
Manisha Pai, 617-245-2107
mpai@bluebirdbio.com
or
Pure
Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com